Sinphar Pharmaceutical Co.,Ltd. Stock

Equities

1734

TW0001734002

Pharmaceuticals

End-of-day quote Taiwan S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
37 TWD +0.14% Intraday chart for Sinphar Pharmaceutical Co.,Ltd. +2.92% +8.98%
Sales 2022 2.86B 88.28M Sales 2023 2.96B 91.56M Capitalization 5.69B 176M
Net income 2022 225M 6.95M Net income 2023 375M 11.59M EV / Sales 2022 2.18 x
Net Debt 2022 669M 20.67M Net Debt 2023 864M 26.69M EV / Sales 2023 2.21 x
P/E ratio 2022
24.8 x
P/E ratio 2023
15.2 x
Employees -
Yield 2022
3.02%
Yield 2023
2.95%
Free-Float 79.95%
More Fundamentals * Assessed data
Dynamic Chart
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 day+0.14%
1 week+2.92%
Current month+1.51%
1 month+1.51%
3 months+12.80%
6 months+13.50%
Current year+8.98%
More quotes
1 week
36.50
Extreme 36.5
37.10
1 month
35.30
Extreme 35.3
38.15
Current year
32.10
Extreme 32.1
38.15
1 year
31.10
Extreme 31.1
41.10
3 years
27.25
Extreme 27.25
47.00
5 years
14.05
Extreme 14.05
68.50
10 years
14.05
Extreme 14.05
68.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 13-05-31
Director of Finance/CFO - 15-08-10
Chief Tech/Sci/R&D Officer - 07-07-31
Members of the board TitleAgeSince
Chairman - 99-06-06
Director/Board Member - 99-06-06
Director/Board Member - 99-06-06
More insiders
Date Price Change Volume
24-05-02 37.2 +0.54% 488,985
24-04-30 37 +0.14% 347,831
24-04-29 36.95 +0.82% 673,815
24-04-26 36.65 -.--% 276,631
24-04-25 36.65 -0.27% 315,250

End-of-day quote Taiwan S.E., April 29, 2024

More quotes
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Company’s principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
More about the company